(Q41957462)

14 October 2017

Spironolactone dose-response relationships in healthy subjects (English)

1 reference

14 October 2017

McInnes GT

1

1 reference

14 October 2017

Perkins RM

series ordinal

2

1 reference

14 October 2017

Shelton JR

series ordinal

3

1 reference

14 October 2017

Harrison IR

series ordinal

4

1 reference

14 October 2017

language of work or name

English

0 references

publication date

1 April 1982

1 reference

British Journal of Clinical Pharmacology

14 October 2017

1 reference

14 October 2017

13

1 reference

14 October 2017

4

1 reference

14 October 2017

513-518

1 reference

Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Agonist and antimineralocorticoid activities of spirolactones

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Spironolactone and potassium canrenoate in normal man

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Sodium diuresis induced by steroidal antagonists of aldosterone.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402049

Canrenone--the principal active metabolite of spironolactone?

18 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1982.TB01413.X

High doses of spironolactone in the treatment of liver cirrhosis with ascites

21 January 2018

1 reference

12 December 2020

Relative potency of prorenoate and spironolactone in normal man

1 reference

12 December 2020

Spironolactone. I. Disposition and metabolism

1 reference

12 December 2020

Spironolactone. III. Canrenone—maximum and minimum steady‐state plasma levels

1 reference

12 December 2020

Spironolactone and canrenoate-K: relative potency at steady state

1 reference

12 December 2020

1 reference

12 December 2020

Activity of sulfur-containing intermediate metabolites of spironolactone

1 reference

12 December 2020

Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate

1 reference

12 December 2020

Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison

1 reference

12 December 2020

Aldosterone antagonists

1 reference

12 December 2020

The effect of an aldosterone antagonist on the renal response to sodium restriction

1 reference

12 December 2020

Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone

1 reference

12 December 2020

The aldosterone blocking effects of spirolactones

1 reference

12 December 2020

A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma

1 reference

12 December 2020

Human assay of electrolyte-active steroids and their antagonists

1 reference

12 December 2020

10.1111/J.1365-2125.1982.TB01413.X

Identifiers

DOI

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

7066166

1 reference